12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (TA1045)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 March 2025
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) (TA938)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 December 2023
Palforzia for treating peanut allergy in children and young people (TA769)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 October 2021
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 October 2019
Omalizumab for previously treated chronic spontaneous urticaria (TA339)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 June 2015
Omalizumab for treating severe persistent allergic asthma (TA278)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2013
Pharmalgen for the treatment of bee and wasp venom allergy (TA246)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 February 2012
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 September 2025
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
CT-P39 (omalizumab biosimilar) for previously treated chronic spontaneous urticaria [TSID11832]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines [ID6356]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over [TSID12082]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years [ID6510]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC